The use of GC in the 6 months prior to and the 6 months following new initiation of TNFi use.
| No. GC Users Prior to New TNFi Use | No. GC Users Following New TNFi Use | p | Mean Daily GC Dose Prior to New TNFi Use (SD) | Mean Daily GC Dose Following New TNFi Use (SD) | Mean Change in Daily GC Dose (95% CI) | p | |
|---|---|---|---|---|---|---|---|
| All new TNFi users, n = 344 | 126 (37%) | 68 (20%) | < 0.0001 | 2.7 mg (5.8) | 1.6 mg (4.8) | −1.1 mg (0.5–1.6) | 0.0002 |
| Prevalent GC users, n = 126 | 126 (100%) | 51 (40%) | < 0.0001 | 7.3 mg (7.7) | 3.9 mg (7.3) | −3.4 mg (2.0–4.9) | < 0.0001 |
GC: glucocorticoids (in prednisone equivalents); TNFi: tumor necrosis factor inhibitors.